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Testing an early online intervention for the
treatment of disturbed sleep during the
COVID-19 pandemic in self-reported good
and poor sleepers (Sleep COVID-19): study
protocol for a randomised controlled trial
Olivia L. Sawdon†, Greg J. Elder*†, Nayantara Santhi, Pamela Alfonso-Miller and Jason G. Ellis
Abstract
Background: Theoretical models of insomnia suggest that stressful life events, such as the COVID-19 pandemic,
can cause acute insomnia (short-term disruptions to sleep). Early interventions may prevent short-term sleep
problems from progressing to insomnia disorder. Although cognitive behavioural therapy for insomnia (CBT-I) is
effective in treating insomnia disorder, this can be time and resource-intensive. Further, online interventions can be
used to deliver treatment to a large number of individuals. The objective of this study is to investigate if an online
behavioural intervention, in the form of a leaflet, which has been successfully used alongside CBT-I for acute
insomnia, can reduce symptoms of acute insomnia in poor sleepers.
Methods: A total of 124 self-reported good and poor sleepers will be enrolled in an online stratified randomised
controlled trial. After baseline assessments (T1), participants will complete a 1-week pre-intervention sleep monitoring
period (T2) where they will complete daily sleep-diaries. Poor sleepers (n = 62) will be randomly allocated to an
invention or wait-list group, where they will receive the intervention (T3), or will do so after a 28-day delay. Good
sleepers (n = 62) will be randomly assigned to an intervention or no intervention group. All participants will complete a
1-week post intervention sleep monitoring period using daily sleep diaries (T4). Participants will be followed up at 1
week (T5), 1 month (T6) and 3months (T7) post intervention. The primary outcome measure will be insomnia severity,
measured using the Insomnia Severity Index. Secondary outcome measures will include subjective mood and
subjective sleep continuity, measured using sleep diaries. Data will be analysed using an intention-to-treat approach.
Discussion: It is expected that this online intervention will reduce symptoms of acute insomnia in self-reported short-
term poor sleepers, and will also prevent the transition to poor sleep in good sleepers. We expect that this will
demonstrate the feasibility of online interventions for the treatment and prevention of acute insomnia. Specific
advantages of online approaches include the low cost, ease of administration and increased availability of treatment,
relative to face-to-face therapy.
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
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Introduction
Background and rationale {6a}
Insomnia is very common and is defined as dissatisfaction with
sleep quantity, sleep quality, or both, due to difficulties initiating
and/or maintaining sleep, for at least 3 nights per week, for a
period of at least 3months [1]. Within industrialised societies,
approximately 6–10% of the population have insomnia, where
prevalence rates have increased in recent years; additionally, up
to 48% of the population report the presence of insomnia
symptoms [2, 3]. Therefore, insomnia is a highly prevalent
problem. Insomnia disorder (beyond 3 months) is associated
with a significant economic burden [4] and is a risk factor for a
range of physical health conditions including hypertension,
cardiovascular diseases and psychological conditions including
depression [5–7].
Theoretical models of insomnia (e.g. Spielman’s “3P”
model) suggest that psychophysiological arousal caused
by a stressful life event can cause a short-term disrup-
tion to sleep (i.e. acute insomnia) [8, 9]. Over time, this
can result in maladaptive compensatory behaviours, such
as spending excessive time in bed or becoming preoccu-
pied with sleep, which consequently creates a long-term
problem of poor sleep through behavioural conditioning
[10]. Acute insomnia is common, where the annual inci-
dence rate is potentially as high as 27 to 37% [11, 12].
One study has demonstrated that approximately 7% of
individuals with acute insomnia subsequently go on to
develop insomnia disorder, and a further 20% of individ-
uals demonstrate variable sleep disturbances and may go
on to develop insomnia disorder, albeit at a slower rate
[12]. Given the associated individual and economic
health burden associated with insomnia disorder, strat-
egies which prevent the transition from acute to chronic
insomnia are important.
Previous naturalistic studies have indicated that stressful
events, in the form of natural disasters such as earthquakes
or hurricanes, or events such as war, can disrupt sleep [13–
16]. The ongoing COVID-19 pandemic may represent one
such stressful life event. A recent meta-analysis has demon-
strated that the global prevalence of sleep problems during
the COVID-19 pandemic is high, where approximately 40%
of the general population and healthcare workers are affected
by sleep disturbances [17]. Individual fear of infection, or per-
ceived infection severity, may also represent a stressor in the
context of the COVID-19 pandemic. For example, one
cross-sectional study from China demonstrated that sleep
disturbances were common, and people who believed that
COVID-19 had caused a higher number or deaths or that
COVID-19 was not easy to cure, were more likely to experi-
ence sleep disturbances [18]. Additionally, one Italian study
has indicated that as well as poor sleep quality being very
common, individuals who had a greater fear of direct contact
with people infected by COVID-19, and those with an uncer-
tain COVID-19 infection status, had an increased risk of de-
veloping sleep disturbances, and higher anxiety and distress
[19]. Therefore, COVID-19 sleep disturbances are extremely
likely, and early interventions may present an opportunity to
prevent a short-term sleep disruption from becoming a long-
term clinical sleep problem [20].
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Pharmacological treatments, such as benzodiazepines,
are often used in the management of insomnia and can
be effective treatments in the short term [21]. However,
pharmacological agents are associated with a range of
side effects and adverse outcomes, including drowsiness,
tolerance, dependency and negative impacts upon next-
day cognition, in addition to increased mortality and sui-
cide risk [21–24]. In particular, the use of pharmaco-
logical agents is particularly problematic in older adults
[25]. Therefore, non-pharmacological alternatives are
necessary.
One non-pharmacological treatment, which is highly
effective in the treatment of chronic insomnia, is cogni-
tive behavioural therapy for insomnia (CBT-I) [21].
CBT-I is a structured psychotherapy with the aim of
identifying and changing maladaptive cognitions and be-
haviours which contribute to the maintenance of insom-
nia [26]. CBT-I results in equivalent improvements to
those observed using pharmacological treatments, with
the benefit of being more durable (compared to pharma-
cological treatment discontinuation) and concomitant
reductions in symptoms of anxiety and depression [21].
For these reasons, CBT-I is recommended as a first-line
treatment for chronic insomnia [21]. However, the wide-
spread delivery and uptake of CBT-I is prevented by the
lack of qualified providers and high attrition levels [20].
Therefore, traditional CBT-I may be too time- and
resource-intensive to be feasible and practical in the
treatment of acute insomnia, and shorter interventions
are likely to be of benefit.
One previous study found that the use of a self-help
leaflet (based on stimulus control, cognitive control and
imagery distraction techniques), delivered alongside a
60–70min single (“one shot”) session of face-to-face
CBT-I for acute insomnia, effectively reduced insomnia
severity [20]. Furthermore, follow-up studies have dem-
onstrated effectiveness when the leaflet has been used
alongside CBT-I treatment, in a group format and in a
male adult prison population [26, 27]. Internet-based in-
terventions can be used to deliver treatment to more in-
dividuals than face-to-face therapists, with lower relative
costs [28]. Therefore, this self-help leaflet is well-suited
to an online delivery model and can be used to reach a
large number of people in the context of a large-scale
stressful event. Indeed, internet-based CBT-I has been
shown to be effective, with similar effect sizes to face-to-
face treatments [29]. In further support of an online de-
livery model, recent studies have also demonstrated that
sleep extension does not occur in the context of acute
insomnia [30, 31]; therefore, incorporating sleep restric-
tion is not necessary. This intervention may also aid the
prevention of sleep problems in individuals with good
sleep, where the stress of a naturalistic event can still
cause sleep disturbances [13–16]. Therefore, this study
will examine if an online self-help leaflet is effective in
reducing symptoms of acute insomnia in poor sleepers.
This study will also examine how long the effects last for
at follow-up stages, and finally, investigate if the leaflet
can prevent the development of poor sleep in good
sleepers.
Objectives {7}
The primary objective of this study is to examine the
effectiveness of an online intervention for poor sleep in
the context of an ongoing stressful major life event. This
will be implemented by assessing if this intervention can
reduce insomnia severity in the short term (1 week post
intervention follow-up) and the long term (1- and 3-
month post intervention follow-ups). It is hypothesised
that the intervention will reduce insomnia severity in
poor sleepers.
Furthermore, the secondary objectives of this study are
to assess if the intervention can (1) reduce subjective
anxiety and depression in good and poor sleepers, (2)
assess if the intervention can improve sleep continuity
(derived from subjective sleep diaries) in good and poor
sleepers and (3) examine if the intervention can prevent
the development of acute insomnia in good sleepers. It
is hypothesised that the intervention will reduce
subjective symptoms of anxiety and depression in good
and poor sleepers, and prevent the development of acute
insomnia in good sleepers, as reflected by lower
insomnia severity scores in those who have received the
intervention.
Trial design {8}
This study is designed as a stratified randomised
controlled trial involving both self-reported good and
poor sleepers. Good sleepers will be randomised into an
intervention or no intervention group using a 1:1 alloca-
tion ratio. Poor sleepers will be randomised into an
intervention or wait list (where participants will receive
the treatment after a 28-day delay) group with a 1:1 allo-
cation ratio. Overall, good and poor sleepers will partici-
pate in the study at a 1:1 ratio (Fig. 1).
Methods: participants, interventions and
outcomes
Study setting {9}
Participants will complete all study procedures
completely online, and this will include the delivery of
the study intervention. There are no geographical
restrictions upon participation.
Eligibility criteria {10}
Both self-reported healthy good sleepers, who do not re-
port any sleep problems, and individuals who report
current sleep problems, where they have experienced
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sleep problems or between 2 weeks and 3 months at the
point of study entry, will be eligible to participate.
Inclusion criteria
Individuals who are good and poor sleepers are eligible to
participate if they meet the following criteria: (1) they are
aged 18 years or above; (2) if they consider themselves to
have a sufficient level of English comprehension to be able
to understand and complete all study measures.
Participants who are self-reported poor sleepers
must meet the criteria for acute insomnia, as defined
by the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5 [1];). Specifically, participants must
report (1) difficulties in falling asleep, staying asleep,
or awakening too early for at least three nights per
week, for a time period of between 2 weeks and 3
months, and (2) distress or impairment due to the
sleep loss. Both criteria must occur despite the indi-
vidual having had an adequate opportunity for sleep.
Exclusion criteria
Participants cannot take part if they (1) report having
chronic sleeping problems that persist more than 3
months immediately prior to consent, (2) are actively
seeking treatment for their sleep problem, (3) have a
self-reported history of head injury or (4) have had a
diagnosis of schizophrenia, epilepsy or personality dis-
order, as the intervention involves distraction techniques
which may increase rumination and subsequently influ-
ence the effectiveness of the sleep intervention.
Fig. 1 Participant flowchart (NB: good sleeper participants who do not receive the intervention will complete the follow-up stages at an equivalent
time point)
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Who will take informed consent? {26a}
Participants will provide informed consent, which will be
recorded electronically.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Participants will be asked for specific additional consent
to allow for their anonymised data to be combined and
used in similar studies, in order to maximise the
scientific value of the data. However, participants can
take part in this study without consenting to the re-use
of their data. Consent for biological specimens is not ap-
plicable, as biological samples are not being collected.
Interventions
Explanation for the choice of comparators {6b}
The behavioural leaflet that will be implemented in this
study has previously been successfully used to reduce
insomnia symptoms (measured on the basis of ISI
scores) in individuals with insomnia and acute insomnia
[20, 26, 27]. In line with our previous studies, we will
compare insomnia severity before and after the
intervention [20, 26, 27]; this is appropriate given that
the primary aim of this study is to examine the short-
term effectiveness of this intervention in poor sleepers.
A wait-list group of poor sleepers, who will receive the
intervention after a 28-day delay, will be also used to
examine drop-out rates in order to inform the use of
wait-list control designs using this intervention in future.
This design is ethically appropriate, as wait-list poor
sleepers will have therefore also the opportunity to re-
ceive the intervention.
Good sleeper comparators will be those who do, and
do not, receive the intervention. This design is
appropriate given the aim of the study.
Intervention description {11a}
Participants, who are eligible to receive the intervention,
will be provided with an online two-page sleep self-help
leaflet in the format of a PDF file. Participants will be
specifically encouraged, and permitted, to download,
save, physically print or take mobile phone screenshots
of the leaflet.
The intervention is an online version of a self-help
leaflet which was used in a previous study [20]. This
self-help leaflet outlines the principles of Stimulus Con-
trol, Cognitive Control and Imagery Distraction tech-
niques [32, 33]. Specifically, the self-help leaflet aims to
improve sleep by identifying and addressing sleep-
related dysfunctional thinking. This is done by providing
education about sleep, techniques to distract from intru-
sive worrisome thoughts at night, and guidelines for
sleep-related stimulus control. These rules to improve
sleep are presented in the format of the “three D’s”:
“Detect”, which provides individuals with instructions
for completing a sleep diary, “Detach” which provides
stimulus control instructions, and “Distract”, which re-
fers to cognitive control and imagery distraction instruc-
tions [20].
Criteria for discontinuing or modifying allocated
interventions {11b}
There are no special criteria for discontinuing or
modifying the allocated interventions. As the intervention
will be self-administered, participants will be free to dis-
continue the treatment whenever they wish to. Similarly,
there are no restrictions on the subsequent use of the
intervention leaflet.
Strategies to improve adherence to interventions {11c}
Participant treatment adherence will be formally
monitored by verifying that individuals have downloaded
or viewed the sleep intervention leaflet. Adherence will be
recorded electronically. There are no specific strategies
that will be used for adherence improvement in this trial.
Relevant concomitant care permitted or prohibited
during the trial {11d}
There are restrictions on pharmacological or non-
pharmacological concomitant care before and during
study participation. This is necessary to verify whether
the intervention can reduce symptoms of acute insom-
nia. However, as the study will be delivered entirely on-
line, the use of concomitant care will not be formally
monitored. Furthermore, individuals who are actively
seeking treatment for their sleep problems, irrespective
of how long they have had the sleep problem, will not be
able to participate in the study.
Provisions for post-trial care {30}
The present study has a minimal risk of side effects and
therefore there is no provision for post-trial care. How-
ever, if any good sleeper participants, who have not re-
ceived the intervention, report the development of
short-term sleep problems during the study, the online
intervention will be offered to them free of charge. This
study is very unlikely to cause any psychological distress,
as the intervention is a safe and established treatment
that has been successful in previous studies in our re-
search group.
Participants will be directed to their general practitioner
(GP) if they are concerned about their physical or
psychological health as a result of taking part in the study.
Northumbria University has insurance to cover non-
negligent harm associated with the study.
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Outcomes {12}
Primary outcomes
The primary outcome measure is the Insomnia Severity
Index (ISI [34];). This will be assessed at baseline,
immediately prior to the intervention, and 1-week, 1-
month and 3-month post intervention.
Secondary outcomes
Secondary outcome measures include subjective mood
and sleep continuity, as follows:
(1) Changes in the 7-item Generalised Anxiety Dis-
order Questionnaire (GAD-7 [35];)
(2) Changes in the 9-item Patient Health Questionnaire
(PHQ-9 [36];)
(3) Changes in subjective sleep continuity, measured
using the Consensus Sleep Diary (CSD-M [37];).
The following variables will be assessed: number of
awakenings (NWAK), wake after sleep onset
(WASO), total sleep time (TST), sleep onset latency
(SOL) and sleep efficiency (SE%).
Subjective sleep continuity will be compared pre-
intervention and post intervention (i.e. in the week be-
fore and after the intervention).
Participant timeline {13}
Figure 2 displays the participant timeline.
Sample size {14}
A total sample size of 124 is required for the present
study. This is based on an a priori power analysis which
was conducted using G*Power 3.1 [38]. It is expected
that there will be an overall drop-out rate of 15% (n =
16) during the study, and therefore, a total sample size
of 124 is required. An equal number of participants will
be recruited to each group (n = 31). Good and poor
sleepers will be recruited at a 1:1 ratio (62:62
participants)
A minimum of 54 poor sleeper participants are required
to assess the primary outcome and meet the study’s
objectives on the basis of an expected medium effect size
(dz = 0.50) at 95% power for the primary outcome
measure. Our research group has previously observed
medium-to-large effect sizes (d = 0.64) when the printed
version of this intervention has been used in people with
insomnia disorder [20], and large effect sizes (dz = 2.35) in
prison inmates with acute insomnia [26], both upon the
Insomnia Severity Index as the primary outcome. Add-
itionally, a recent meta-analysis of internet-delivered cog-
nitive behavioural therapy for insomnia observed large
effect sizes upon insomnia severity (g = 0.89 when ad-
justed for publication bias; unadjusted g = 1.09) [29].
Therefore, on this basis, a medium effect size is expected
for the present study. A minimum of 54 good sleeper par-
ticipants are required to assess the primary outcome on
the basis of an expected medium effect size (f2 = 0.25).
For poor sleepers, the a priori power analysis was
calculated on the basis of the primary outcome measure
(ISI) being compared between baseline and 1-week
follow-up for poor sleepers, using a two-tailed repeated-
measures t-test (dz = 0.50; 95% power). For good
sleepers, the a priori power analysis was calculated on
the basis of the primary outcome measure being com-
pared using a 2 (group) × 2 (time point: baseline vs. 1-
Fig. 2 SPIRIT figure and overview of enrolment, interventions and assessments
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week follow-up) mixed analysis of variance (ANOVA),
with a medium effect size (f2 = 0.25).
Recruitment {15}
Participants will be predominantly recruited online. The
study URL will be placed online and publicised to
potential participants using the Northumbria University
website and various social media channels, including the
Northumbria University Twitter and Facebook platforms.
The URL will also be included on the ISRCTN trial
registration page. Participants will not receive any
financial incentive and the intervention will be offered to
individuals free of charge.
Assignment of interventions: allocation
Sequence generation {16a}
The allocation sequence and randomisation will be
automatically generated using the survey software
(Qualtrics). Good sleepers (n = 30) will be randomly
allocated using a 1:1 ratio into either an intervention or
no-intervention group. Poor sleepers (n = 30) will be
randomised into an intervention or wait-list group, with
a 1:1 allocation.
Concealment mechanism {16b}
All participants who fulfil the inclusion criteria, and
provide informed consent, will be randomised and given
a unique identification number in Qualtrics prior to
completing the baseline assessments. Qualtrics will
automatically allocate participants to the appropriate
study condition and section after they have entered the
study and indicated whether they are a good or poor
sleeper. Concealment will therefore be assured, as
members of the research team will be completely unable
to determine which arm of the study good, or poor,
sleepers have been allocated to until after study entry.
Implementation {16c}
The allocation sequence will be automatically generated
by the Qualtrics software without any influence from any
member of the research team. Participants will be
allocated a numeric group identification code in the study
dataset to denote group allocation, as follows: 1 = good
sleeper (no intervention); 2 = good sleeper (intervention);
3 = poor sleeper (wait list) or 4 = poor sleeper.
Assignment of interventions: blinding
Who will be blinded {17a}
Due to the nature of the intervention, participants will
be aware of which condition they have been allocated to,
so they cannot be blinded to the study. However, the
member of the research team who will be conducting
the statistical analysis will be blinded to the study
condition until all data analysis has been undertaken.
Any routine data monitoring will be undertaken by a
member of the research team who will not be
responsible for conducting the statistical analysis.
Procedure for unblinding if needed {17b}
Participant-level code breaks will only occur in
emergency circumstances, where the knowledge of the
group assignment is judged to be clinically essential for
the management of the individual. However, the risk of
this situation occurring is considered to be extremely
low, given the safety profile of the intervention, and it is
not expected that this will be necessary during the trial.
In a situation where an emergency code break is judged
to be essential by the principal investigator, an
independent member of the study team, who will not
have the responsibility for undertaking statistical
analyses, will be permitted to break the blinding by
accessing the stored dataset. If a code break does occur,
the principal investigator will maintain the blind as
much as possible. Whilst the allocation will be known to
the participant, in all circumstances, the allocation will
not be disclosed to any other study personnel. The
written or verbal disclosure of the code will only be
done where this is clinically necessary. All code breaks
will be documented.
Data collection and management
Plans for assessment and collection of outcomes {18a}
The entire study will be conducted online. The full list of
assessments and time points of completion are presented
in Fig. 2 and are described below in more detail.
In addition to the intended primary and secondary
outcome measures, participants will complete measures of
general health status, subjective stress, sleepiness and
dreaming. This will facilitate subsequent exploratory data
analyses, either alone or in combination with data from
other studies. This is because, for example, these
measures are potentially altered by insomnia (e.g. in the
case of dream content [39, 40]), or because they might be
involved in causing sleep disturbances (e.g. stress [41]).
Demographic and physical/psychiatric health information
Participants will be asked brief demographic questions,
including their educational level, month and year of
birth, and occupational information (e.g. their current
job title, employment sector and role). Participants will
also be asked whether or not they were furloughed (i.e.
that they were placed on a paid temporary leave of
absence from work by their employer), or were made
unemployed during this period. Participants will be
asked for a very brief self-reported physical and psychi-
atric medical history, including a list of current medica-
tion. Participants will also be asked specific yes/no
questions in relation to COVID-19. This will include
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whether they have had a test for, a diagnosis of, or have
demonstrated symptoms of COVID-19.
General health status
In order to characterise the general health status and
health-related quality of life of participants, they will
complete the 36-Item Short Form Survey Instrument
(SF-36 [42];). This assesses eight domains, including
physical function, role limitations because of physical
health problems, bodily pain, general health perceptions,
general mental health, role limitations because of mental
health problems, social functioning and vitality. These
are used to generate SF-36 scores ranging from 0 to 100,
where higher scores represent better function. The SF-
36 has good reliability and validity [43].
Sleep
Participants will complete the following sleep, sleepiness
and sleep-related measures:
Sleep Disorders Symptom Checklist-25 (SDS-CL-25 [44];)
This is a measure of the presence or absence of six
common sleep disorders (insomnia, obstructive sleep
apnea, restless legs syndrome/periodic limb movement
disorders, circadian rhythm sleep-wake disorders, narco-
lepsy or parasomnias). Individuals are provided with a
list of 25 symptom statements (e.g. “I am tired, fatigued
or sleepy during the day”) and are asked to indicate the
frequency of the particular symptom. The SDS-CL-25
provides an indication of severity and morbidity of a par-
ticular sleep disorder and is used in the present study as
a research screening tool to assess the presence of any
sleep disorder.
Insomnia Severity Index (ISI [34];)
The ISI is a seven-item measure of insomnia, which
assesses the nature, severity and effect of insomnia. The
ISI provides scores ranging from 0 to 28, where high
scores represent more severe insomnia. Whilst originally,
a cut-off score of ≥ 8 is used to identify subclinical in-
somnia from an absence of insomnia, a cut-off score of
≥ 10 will be used since this is optimal for identifying in-
somnia caseness in community samples [45]. As per pre-
vious studies [20], the ISI will be modified from the
original measure to assess insomnia severity during the
previous week, as opposed to the preceding month, in
line with subjective sleep diaries. The ISI is a reliable
and valid measure for quantifying perceived insomnia
severity [34].
Consensus Sleep Diary (CSD-M [37];)
The CSD-M is a subjective sleep diary which will be
used to measure sleep over a period of seven continuous
days. Sleep continuity measures, including total sleep
time (TST), time in bed (TIB), number of awakenings
(NWAK), wake after sleep onset (WASO), sleep onset
latency (SOL) and sleep efficiency (SE%) will be derived
from completed diaries.
Karolinska Sleepiness Scale (KSS [46];)
The KSS is a measure of subjective sleepiness, where
sleepiness in the previous ten minutes is rated using a 9-
point scale, where higher scores represent a greater level
of sleepiness. The KSS has good validity [47].
Mannheim Dream Questionnaire (MADRE [48];)
The MADRE is used to measure the frequency,
content and emotional tone of dreams, in addition to
nightmare frequency and distress. The MADRE has high
levels of test-retest reliability [48].
Psychological measures
Participants will complete the following measures:
Spielberger State-Trait Anxiety Inventory (STAI [49];)
The six-item short-form version of the state scale will
be used to assess situational (state) anxiety symptoms, at
the same time as sleep diary data. The STAI asks partici-
pants to indicate how they are feeling at that particular
point in time, by indicating their level of agreement with
a given statement (e.g. “I feel calm”) to which they re-
spond using a Likert scale. Higher scores represent more
state anxiety. The STAI has good reliability and validity
and is sensitive to the individual changes in state anxiety
[49].
Generalised Anxiety Disorder Questionnaire (GAD-7 [35];)
The GAD-7 is a seven-item questionnaire which as-
sesses subjective anxiety symptoms, providing a score of
between 0 and 21, where higher scores represent more
severe anxiety. The GAD-7 has good validity and reli-
ability [50].
Patient Health Questionnaire (PHQ-9 [36];)
The PHQ-9 is a nine-item questionnaire which as-
sesses subjective depression severity and provides a score
of between 0 and 27, where higher scores represent
more severe depression. The PHQ-9 has high validity
and reliability [51].
Perceived Stress Scale (PSS [52];)
This measures the extent to which life situations in
the preceding month are perceived as being stressful and
consists of 14 items. Total possible scores on the PSS
range from zero to 56, with higher scores representing
higher levels of perceived stress. The PSS has good
validity and reliability [53, 54].
COVID-19 infection susceptibility and distress measures
Participants will be asked to complete two measures in
relation to COVID-19, where they will be asked to indi-
cate their levels of subjective distress in relation to the
pandemic, as well as their perceived infection
susceptibility.
The Impact of Event Scale-Revised (IES-R [55];)
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The IES-R is a 22-item self-report measure which
quantifies subjective distress caused by a specific stress-
ful or traumatic life event, by asking participants to indi-
cate how distressed they were with regard to specific
difficulties in the previous week. The IES-R provides a
total score ranging from 0 to 88, where higher scores
represent greater distress.
Perceived Vulnerability to Disease questionnaire (PVD
[56];)
The PVD is a 15-item self-report measure which as-
sesses perceived susceptibility to infectious diseases and
assesses emotional discomfort in situations with the po-
tential for high infection transmission, with two separate
subscales (Germ Aversion and Perceived Infectability).
Plans to promote participant retention and complete
follow-up {18b}
To promote participant retention, participants will
receive automated email reminders at each stage of the
study. Participants will also be encouraged to contact
the study team if they require support during the trial.
Data management {19}
All study data will be electronic and will be obtained
directly from Qualtrics. Participant informed consent
will be provided electronically and all CRFs and
associated documentation will be electronic. The online
component of the study, and resulting dataset, will be
extensively tested and checked prior to the first
participant enrolment, to ensure that all methods of data
entry are reliable. Furthermore, the full dataset will be
checked and verified for integrity and quality at regular
intervals during the study. This will also be done at the
end of the study by the research team. Any necessary
changes to the dataset will be fully documented using a
written log. Throughout the trial, anonymised data,
relevant documentation and CRFs will be stored on
secure, password-protected computer storage that will
only be accessible to the research team and will be
backed up regularly. At the end of the study, data will be
exported to appropriate statistical analysis software.
Confidentiality {27}
In order to protect participant confidentiality, all
personal data will be regarded as being strictly
confidential and the study will comply with the
requirements of the General Data Protection Regulation
(GDPR). Participant email addresses will be used for the
sole purpose of sending participants reminders to
complete their daily sleep diary, and at appropriate
follow-up stages of the study. Participant email addresses
will be deleted upon study completion. Anonymised data
will be stored on secure, password-protected computer
storage that will be accessible only by authorised
members of the research team. All electronic data will
be stored in line with standard Northumbria University
retention guidelines and in accordance with all other
relevant legislation (e.g. GDPR).
In order to maximise the scientific value of the
dataset, we intend to combine anonymised data from
this study with data from similar studies conducted
within this research group, and where possible, larger
collaborative studies. Provision has been made in the
participant consent form to allow for this and
participants will be permitted to opt out of this if they
wish to do so.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
This is not applicable: biological samples will not
collected as part of this trial.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Statistical analysis is pre-specified in the protocol and
will be conducted either at the end of the study, or when
the recruitment target is met. Statistical analyses will be
conducted by a member of the team who will not have
any role in monitoring the data during the study. In
order to meet the aims of the study, the statistical ana-
lysis will assess poor and good sleepers separately.
In poor sleepers, the short-term effectiveness of the
primary outcome measure (ISI) will be analysed by com-
paring pre/post intervention ISI scores, at baseline (day
28 for waitlist poor sleepers) and 1-week follow-up,
using a repeated-measures t-test. The longer-term effect-
iveness of the primary outcome measure will be assessed
by comparing baseline, 1-week, 1-month and 3-month
follow-up time points, using a one-way analysis of vari-
ance (ANOVA) with an expected main effect of time. A
significant main effect will be followed up using post
hoc tests as appropriate. Non-parametric equivalent tests
will be used if appropriate. Effect sizes (dz or partial eta
squared) will be used to demonstrate effectiveness. Sec-
ondary outcome measures (GAD-7, PHQ-9) will be
assessed in the same manner, with the exception of
CSD-M sleep continuity variables, which will be com-
pared pre and post intervention using repeated-
measures t-tests, where sleep continuity p values will be
adjusted for multiple comparisons. The drop-out rate of
the wait list poor sleepers will also be examined and will
be expressed as a number and as a percentage of partici-
pants, in order to inform the design of future trials.
In good sleepers, the short-term effectiveness of the
intervention will be assessed by comparing good sleepers
who have, and have not, received the intervention, using
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a 2 (group) × 2 (time point: baseline vs. 1-week follow-
up) mixed ANOVA with an expected significant inter-
action, which will be followed up using post hoc tests.
The longer-term effectiveness will be examined using a
2 (group) × 4 (time point: baseline vs 1-week vs. 1-
month vs. 3-month follow-up), with an expected signifi-
cant interaction, which will be followed up using post
hoc tests. Effect sizes (partial eta squared) will be used
to demonstrate effectiveness. Secondary outcome mea-
sures (GAD-7, PHQ-9) will be assessed in the same
manner, with the exception of CSD-M sleep continuity
variables, which will be compared pre and post interven-
tion using repeated-measures t-tests, where sleep
continuity p values will be adjusted for multiple
comparisons.
Remission rates will be calculated on the basis of a
score of 10 or more on the ISI at follow-up and as a per-
centage of groups. In the good sleeper participants, those
who transition to subsequently having insomnia will be
defined as doing so on the basis of an ISI score of < 10
points at baseline, and > 10 points at follow-up stages.
Interim analyses {21b}
Interim analyses are not planned.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
No other additional analyses are planned.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
Data will be analysed using an intention-to-treat ap-
proach. Large participant drop-out rates are not antici-
pated and any expected drop-outs are factored into the
target sample size. The primary outcome analysis will be
based only on the complete case/observed outcomes,
and imputation of missing data will not take place, since
there is no reason to believe that participants who may
be lost to follow-up will occur randomly.
Plans to give access to the full protocol, participant-level
data and statistical code {31c}
The dataset, protocol and statistical code (if applicable) will
be made available to appropriately qualified investigators
upon reasonable request to the principal investigator. Our
intended policy is that the research team will have exclusive
use of the data for a period of 12months from the end of the
project, or until the data is published, if this is required
alongside publications.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
As this is a study with an extremely low risk of side effects
due to the behavioural nature of the intervention, a formal
Trial Steering Committee is not required. The trial will be
managed and monitored locally by a study management
group consisting of the named investigators, who will meet
on a fortnightly basis. Quality control will be maintained
through adherence to all relevant Northumbria University
standard operating and research governance procedures and
the principles of Good Clinical Practice.
Composition of the data monitoring committee, its role
and reporting structure {21a}
A Data Monitoring Committee is not required in this
study due to the intervention having only an extremely
low risk of side effects.
Adverse event reporting and harms {22}
This is a low-risk trial. However, the protocol does have
provision for adverse events (AEs), where all AEs will be
reported and categorised as to expectedness, relatedness
and severity. The severity of all AEs will be graded on a
3-point scale of intensity (mild, moderate, severe). For
the purposes of this study, any adverse events (AEs)
which the investigators are notified of during the study
(i.e. from study entry to the final study measure) will be
recorded. If an AE occurs, the research team will have
access to all data accrued to that point and will have the
power to terminate the trial early.
Frequency and plans for auditing trial conduct {23}
Routine trial conduct will be monitored by the research
team. The research team will permit the relevant
Northumbria University ethics committee, and sponsor,
to conduct study-related monitoring and audits, when
this is specifically requested. The research team will pro-
vide direct access to source data and study documenta-
tion, if required.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
Any modifications to the protocol which may impact
upon the conduct of the study (e.g. the study objectives,
design, population, proposed sample size or procedures)
will require a formal amendment to the protocol, and an
ethical amendment. Modifications will be formally
documented on the most recent version of the study
protocol, where a summary of changes will be provided.
The ISRCTN record will also be updated.
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Dissemination plans {31a}
It is anticipated that the overall results of this study will
be submitted to an appropriate peer-reviewed publica-
tion within 12months of study completion. The results
of the study will also be presented at relevant national
and international scientific meetings. Participants will be
able to request a summary of the study results upon
completion of the study, and we will aim to provide a
summary of findings on the Northumbria University
website.
Discussion
The main objective of this online randomised controlled
trial is to investigate the effectiveness of a web-based be-
havioural intervention for poor sleep in the context of
the ongoing COVID-19 pandemic. It is expected that
this intervention will reduce insomnia severity in the
short term, and long term, in poor sleepers who receive
the intervention. Secondary objectives of this trial will
include assessing if the intervention can improve sub-
jective anxiety, depression and sleep continuity in poor
sleepers, and if the intervention can prevent good
sleepers from developing acute insomnia. It is expected
that the intervention will improve subjective anxiety, de-
pression and sleep continuity in poor sleepers and that
the intervention will prevent the transition from good
sleep to acute insomnia.
If, as expected, the behavioural intervention is
effective, this study will have a number of implications.
Whilst we have previously successfully used this
intervention alongside face-to-face CBT in a range of
populations [20, 26, 27], disadvantages of this approach
can include the requirement of trained personnel and
the associated time and costs. Specific advantages of an
online intervention approach include the low cost and
ease of administration, and relative scalability, since on-
line interventions can potentially reach more individuals
with insomnia complaints than face-to-face therapists,
and this mode of treatment delivery is generally accept-
able to individuals [28, 57]. This is also cost-effective,
since internet-based CBT-I can be used to deliver ther-
apy to a greater number of individuals than would be
possible in-person using the same number of practi-
tioners [28]. Additionally, online interventions have ad-
vantages in the context of COVID-19, since these
interventions can be delivered without accommodating
for social distancing measures, or fear of contamination,
which may be problematic or require additional re-
sources [58]. If feasible and effective, this would be use-
ful in terms of both the prevention and treatment of
acute insomnia. This is very likely to have subsequent
economic benefits, both in terms of prevention and
treatment: poor sleepers have an economic cost to soci-
ety which is ten times greater than good sleepers [4].
This study may also have implications for future acute
insomnia trial design. To date, no studies have examined
the long-term effectiveness of this behavioural interven-
tion for acute insomnia, when it has been delivered on-
line. It is possible that to retain any benefits, in good
and poor sleepers, “booster” behavioural interventions,
or additional support, may be required [20], and this
could be examined in future trial designs.
This study is likely to have four main limitations. Firstly,
although the study has been designed with an anticipated
drop-out rate of 20%, evidence from other online behav-
ioural interventions has shown that the drop-out rate may
be higher when CBT interventions are delivered online in-
stead of in-person [59]. This also appears to be problem-
atic in the context of insomnia research, where attrition
rates may be as high as 50% [57]. Secondly, a further
potential limitation is that the provision of additional sup-
port may be necessary to maintain effectiveness. For ex-
ample, evidence from internet-based CBT for depressive
and anxiety symptoms indicates that support can increase
adherence and the subsequent effectiveness of the treat-
ment programme [60], and this is also the case in insom-
nia treatment when it is delivered online [61]. However,
one limitation of providing support is that this may re-
quire additional cost and staffing resources, since the
provision of human feedback typically requires 15–30min
of work per participant per treatment session [28]. As an
alternative, automated methods of feedback may be effect-
ive whilst retaining the low costs of an online delivery
model [28].
Thirdly, it is acknowledged that a further limitation of
the study is in the open-label design, and the fact that
the primary endpoint is participant-reported, which has
the potential to result in detection bias or assessment
bias [62]. However, the Insomnia Severity Index, which
is being used as the primary endpoint, is a reliable and
valid instrument of detecting insomnia in the population
and is sensitive to treatment response [45]. Whilst the
choice of outcome measure is therefore appropriate
given the aims of the present study, future trials may
wish to address these potential limitations.
Finally, it is not possible to formally monitor
treatment adherence in the present study. We have tried
to mitigate the lack of formal monitoring by
electronically verifying that participants have viewed the
intervention leaflet, and by providing instructions which
specifically encourage participants to download, save
and print the behavioural leaflet and to refer to this
whenever they wish to do so. However, it is still possible
that there will be a large variation in adherence, where
some participants may only use the leaflet for a very
short period of time, and other participants are likely to
refer to this on a regular basis. These potential
limitations are likely to be outweighed by the fact that
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the present study design will provide an indication of
the effectiveness of internet-based behavioural interven-
tions for acute insomnia in large-scale, representative,
“real-world” situations [57].
Overall, there is a clear need for treatments which
prevent the transition from acute to chronic insomnia,
given the associated health and economic burden
associated with insomnia. If effective, web-based behav-
ioural interventions which prevent this transition will be
of benefit. Additionally, interventions which prevent
good sleepers from developing sleep disturbances during
stressful naturalistic events are also likely to be of indi-
vidual and societal benefit, and one specific advantage if
they are shown to be effective, is that they can be very
quickly rolled out to targeted populations.
Trial status
The current version of the study protocol is Version 1.1
(date: October 22, 2021). The study is currently open to
participants and recruitment began on August 17, 2020.
It is expected that recruitment will be complete by April
2022. As of 11 October 2021, a total of 377 participants
have provided informed consent.
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